Form 4 for SYRE Spyre Therapeutics, Inc.
Accepted 2026-08-05 21:31:09 ET · period of report 2026-08-03 · accession 0001636282-26-000099 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-08-05 21:31 | 2026-08-03 | SYRE | Turtle Cameron | CEO, Dir | S - Sale | $95.51 | -15.0K | 567.5K | -3% | -$1.43M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-03 | S | D | 800 | $93.97 | 581,740 | D | — | — | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. (F2) The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $93.42 to $94.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. (F3) Includes 58,108 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. |
| 2 | Common | Common Stock | 2026-08-03 | S | D | 7,157 | $95.10 | 574,583 | D | — | — | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. (F4) The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $94.44 to $95.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. (F3) Includes 58,108 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. |
| 3 | Common | Common Stock | 2026-08-03 | S | D | 5,635 | $95.93 | 568,948 | D | — | — | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. (F5) The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $95.45 to $96.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. (F3) Includes 58,108 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. |
| 4 | Common | Common Stock | 2026-08-03 | S | D | 1,392 | $96.82 | 567,556 | D | — | — | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. (F6) The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $96.45 to $97.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. (F3) Includes 58,108 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. |
| 5 | Common | Common Stock | 2026-08-03 | S | D | 16 | $97.46 | 567,540 | D | — | — | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. (F7) The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $97.46 to $97.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. (F3) Includes 58,108 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. |